Phaseline

Companies › ImmVira Pharma

ImmVira Pharma: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
T3011
Oncolytic adenovirus
–Phase 2Nonmuscle-invasive Bladder CancerDec 2028
MVR-T3011
Unclear mechanism for code-named investigational drug
–Phase 1Solid TumorJan 2027
C5252
Oncolytic herpes virus
–Phase 1Glioma, MalignantDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04370587MVR-T3011Phase 1Solid TumorOncologyJan 2027
NCT07243340C5252Phase 1Glioma, MalignantOncologyDec 2027
NCT06971614T3011Phase 2Nonmuscle-invasive Bladder CancerOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Allotera Therapeutics PersonGen BioTherapeutics (Suzhou) Vyriad Shanghai Juncell Therapeutics Scancell

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.